169 related articles for article (PubMed ID: 35314795)
1. CXCL9 inhibits tumour growth and drives anti-PD-L1 therapy in ovarian cancer.
Seitz S; Dreyer TF; Stange C; Steiger K; Bräuer R; Scheutz L; Multhoff G; Weichert W; Kiechle M; Magdolen V; Bronger H
Br J Cancer; 2022 Jun; 126(10):1470-1480. PubMed ID: 35314795
[TBL] [Abstract][Full Text] [Related]
2. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
[TBL] [Abstract][Full Text] [Related]
3. The developing landscape of combinatorial therapies of immune checkpoint blockade with DNA damage repair inhibitors for the treatment of breast and ovarian cancers.
Zhu L; Liu J; Chen J; Zhou Q
J Hematol Oncol; 2021 Dec; 14(1):206. PubMed ID: 34930377
[TBL] [Abstract][Full Text] [Related]
4. Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies.
Minnar CM; Chariou PL; Horn LA; Hicks KC; Palena C; Schlom J; Gameiro SR
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764364
[TBL] [Abstract][Full Text] [Related]
5. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
[TBL] [Abstract][Full Text] [Related]
6. Association of PD-L1 expression by immunohistochemistry and gene microarray with molecular subtypes of ovarian tumors.
Chin CD; Fares CM; Campos M; Chen HW; Shintaku IP; Konecny GE; Rao J
Mod Pathol; 2020 Oct; 33(10):2001-2010. PubMed ID: 32404957
[TBL] [Abstract][Full Text] [Related]
7. Human adipose-derived mesenchymal stem cells prevent type 1 diabetes induced by immune checkpoint blockade.
Kawada-Horitani E; Kita S; Okita T; Nakamura Y; Nishida H; Honma Y; Fukuda S; Tsugawa-Shimizu Y; Kozawa J; Sakaue T; Kawachi Y; Fujishima Y; Nishizawa H; Azuma M; Maeda N; Shimomura I
Diabetologia; 2022 Jul; 65(7):1185-1197. PubMed ID: 35511238
[TBL] [Abstract][Full Text] [Related]
8. Programmed cell death ligand 1 disruption by clustered regularly interspaced short palindromic repeats/Cas9-genome editing promotes antitumor immunity and suppresses ovarian cancer progression.
Yahata T; Mizoguchi M; Kimura A; Orimo T; Toujima S; Kuninaka Y; Nosaka M; Ishida Y; Sasaki I; Fukuda-Ohta Y; Hemmi H; Iwahashi N; Noguchi T; Kaisho T; Kondo T; Ino K
Cancer Sci; 2019 Apr; 110(4):1279-1292. PubMed ID: 30702189
[TBL] [Abstract][Full Text] [Related]
9. Reverse Translation Identifies the Synergistic Role of Immune Checkpoint Blockade and IL15 to Enhance Immunotherapy of Ovarian Cancer.
Felices M; Wesley E; Bendzick LE; Kodal B; Hopps R; Grzywacz B; Hinderlie P; Miller JS; Geller MA
Cancer Immunol Res; 2023 May; 11(5):674-686. PubMed ID: 36807510
[TBL] [Abstract][Full Text] [Related]
10. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
[TBL] [Abstract][Full Text] [Related]
11. CXCL9/10-engineered dendritic cells promote T cell activation and enhance immune checkpoint blockade for lung cancer.
Lim RJ; Salehi-Rad R; Tran LM; Oh MS; Dumitras C; Crosson WP; Li R; Patel TS; Man S; Yean CE; Abascal J; Huang Z; Ong SL; Krysan K; Dubinett SM; Liu B
Cell Rep Med; 2024 Apr; 5(4):101479. PubMed ID: 38518770
[TBL] [Abstract][Full Text] [Related]
12. Manipulating the Wnt/β-catenin signaling pathway to promote anti-tumor immune infiltration into the TME to sensitize ovarian cancer to ICB therapy.
Wall JA; Meza-Perez S; Scalise CB; Katre A; Londoño AI; Turbitt WJ; Randall T; Norian LA; Arend RC
Gynecol Oncol; 2021 Jan; 160(1):285-294. PubMed ID: 33168307
[TBL] [Abstract][Full Text] [Related]
13. Biomarkers that may predict response to immunotherapy in ovarian malignancies.
Chin CD; Fares CM; Konecny GE; Rao J
Curr Opin Obstet Gynecol; 2020 Feb; 32(1):84-90. PubMed ID: 31804230
[TBL] [Abstract][Full Text] [Related]
14. Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade.
House IG; Savas P; Lai J; Chen AXY; Oliver AJ; Teo ZL; Todd KL; Henderson MA; Giuffrida L; Petley EV; Sek K; Mardiana S; Gide TN; Quek C; Scolyer RA; Long GV; Wilmott JS; Loi S; Darcy PK; Beavis PA
Clin Cancer Res; 2020 Jan; 26(2):487-504. PubMed ID: 31636098
[TBL] [Abstract][Full Text] [Related]
15. Local and Targeted Delivery of Immune Checkpoint Blockade Therapeutics.
Han X; Li H; Zhou D; Chen Z; Gu Z
Acc Chem Res; 2020 Nov; 53(11):2521-2533. PubMed ID: 33073988
[TBL] [Abstract][Full Text] [Related]
16. Carboplatin and programmed death-ligand 1 blockade synergistically produce a similar antitumor effect to carboplatin alone in murine ID8 ovarian cancer model.
Zhu X; Xu J; Cai H; Lang J
J Obstet Gynaecol Res; 2018 Feb; 44(2):303-311. PubMed ID: 29171115
[TBL] [Abstract][Full Text] [Related]
17. Atezolizumab and blockade of LncRNA PVT1 attenuate cisplatin resistant ovarian cancer cells progression synergistically via JAK2/STAT3/PD-L1 pathway.
Chen Y; Li F; Li D; Liu W; Zhang L
Clin Immunol; 2021 Jun; 227():108728. PubMed ID: 33878452
[TBL] [Abstract][Full Text] [Related]
18. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.
Mace TA; Shakya R; Pitarresi JR; Swanson B; McQuinn CW; Loftus S; Nordquist E; Cruz-Monserrate Z; Yu L; Young G; Zhong X; Zimmers TA; Ostrowski MC; Ludwig T; Bloomston M; Bekaii-Saab T; Lesinski GB
Gut; 2018 Feb; 67(2):320-332. PubMed ID: 27797936
[TBL] [Abstract][Full Text] [Related]
19. Neutralization of PD-L2 is Essential for Overcoming Immune Checkpoint Blockade Resistance in Ovarian Cancer.
Miao YR; Thakkar KN; Qian J; Kariolis MS; Huang W; Nandagopal S; Yang TTC; Diep AN; Cherf GM; Xu Y; Moon EJ; Xiao Y; Alemany H; Li T; Yu W; Wei B; Rankin EB; Giaccia AJ
Clin Cancer Res; 2021 Aug; 27(15):4435-4448. PubMed ID: 34011561
[TBL] [Abstract][Full Text] [Related]
20. ERK Inhibition Improves Anti-PD-L1 Immune Checkpoint Blockade in Preclinical Pancreatic Ductal Adenocarcinoma.
Henry KE; Mack KN; Nagle VL; Cornejo M; Michel AO; Fox IL; Davydova M; Dilling TR; Pillarsetty N; Lewis JS
Mol Cancer Ther; 2021 Oct; 20(10):2026-2034. PubMed ID: 34349003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
